Progress on target therapy in colorectal cancer
10.3760/cma.j.issn.1006-9801.2010.07.002
- VernacularTitle:转移性结直肠癌分子靶向治疗临床研究进展
- Author:
Aiping ZHOU
;
Fengyi FENG
- Publication Type:Journal Article
- Keywords:
Colorectal neoplasms;
Target therapy;
Antibodies,monoclonal
- From:
Cancer Research and Clinic
2010;22(7):436-439
- CountryChina
- Language:Chinese
-
Abstract:
Target therapy is a major progress in treatment of advanced colorectal cancer. Cetuximab and bevacizumab are the most widely used target agents in colorectal cancer, which target against EGFR and VEGF respectively. The addition of target agent to chemotherapy improve efficacy and prolong survival in the first line setting, as well as in the second line setting. The increased respectability of liver metastases from colorectal cancer is of great importance, k-ras gene mutation is a definite predictor of cetuximab, however, there is no clear predictor for bevacizumab.
